TeamDrive
RUS

Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

22 June 2015

June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

Full video is published at Vedomodsti web-site

According to Leonid Melamed, “The time of uncertainty is exactly the time when management should make important decisions both tactical and strategical that are usually postponed in other times or at least realized in a milder way. This is the right time to allocate internal resources aimed to ensure competitive advantages and to cut down the resources spent on the products, processes and areas that do not bring any competitive value in tactical viewpoint. Such periods are the time to reallocate strategic investments in something that will provide competitive value in 3 to 5 years when stability will come in place of uncertainty. Business model also must be changed, if necessary.

In other words, hard times create a welcomed opportunity for drastic changes that were difficult to realize under regular circumstances.”

In hard times, each business unit of the company is a key point. Such circumstances act as a rich soil to grow brilliant ideas and define the company’s future development. And only highly coordinated operation of all business units may lead the company to a success.

The Vedomosti’s FocusForum Conference will take place June 25, 2015, and bring together various experts who will share their ideas and valuable experience and try to identify an action plan for the future. General Managers, Heads of Business Development, HR, Marketing, Advertising and PR will introduce their business cases and strategies during panel discussions, presentations and unofficial personal meetings.

FocusForum web-site


Previous publication Next publication

Media Center

  • 22 September 2017

    SPIC’s will ensure more predictability for pharmaceutical companies in Russia

    A meeting of the working group of the Coordination Council in the Area of Circulation of Medicines and Medical Devices held in the Russian Union of Industrialists and Entrepreneurs (RSPP) examined the state and development prospects of manufacturing the drugs for the treatment of oncological diseases in Russia.

  • 22 September 2017

    Cancer biobank Indivumed and CRO Helomics team up on precision medicine

    Indivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical datIndivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical data collected from patients around the world to help advance research in personalized cancer treatments. collected from patients around the world to help advance research in personalized cancer treatments.

  • 21 September 2017

    In a world of change, big pharma remains a constant

    Analysts casting their eyes forward to 2022 see big pharma maintaining its position in the sector, protected by vast war chests and ready to pounce on any newcomer that shows promise. Here pharmaphorum’s Andrew McConaghie crunches the numbers.

  • 20 September 2017

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation. The Russians have been pressuring foreign pharmaceutical companies to engage in local production if they want to be in its market. Earlier this year, Russia-based NovaMedica announced it began work on a new plant in Russia’s Kaluga region where it will produce 30 of Pfizer’s sterile injected generic medications for the local market.

Read more